← Eichor
Study identifier: NCT07490132 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Endoscopic Retrograde Cholangiopancreatography

Condition: Gastro-Intestinal Disorder  ·  Sponsor: Methodist Health System

PhaseN/A
Planned participants100
Who can joinAll sexes, 15 Years to no upper limit
Healthy volunteersNo

About this study

The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.

This description comes directly from the study's public registry record.

Talk to the study team

Crystee Cooper, DHEd  ·  214-947-1280  ·  ClinicalResearch@mhd.com

Kavya Mankulangara  ·  214-947-4604  ·  ClinicalResearch@mhd.com

Always discuss trial participation with your own doctor first.

Locations (1)

Methodist Dallas Medical Center- Clinical Research InstituteDallas, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07490132